Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07199517 · ClinicalTrials.gov registry record · NA

Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit

A NA study of Tobacco Use and Cigarette Smoking, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
NA
Development phase
472
Enrollment target
1
Study location

NCT07199517: Recruiting NA study of Tobacco Use and Cigarette Smoking, sponsored by Abramson Cancer Center at Penn Medicine.

NCT07199517 is a NA study of Tobacco Use and Cigarette Smoking that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 472 participants, above the 373-participant average among 76 other Tobacco Use trials with a reported enrollment target (27% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07199517, a NA study of Tobacco Use and Cigarette Smoking, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
NA
Development phase
472 participants
Enrollment target
1
Study location

Study Summary

This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be randomized 2:1 to choose one of three harm-reduction products (ECIG, IQOS, ONP) versus a medicinal nicotine control condition (nicotine patch + lozenge, NPL), receive a 4-week starter product regimen, and then be followed for 6 months to assess use behavior.

Primary Outcome

Seven-day point prevalence smoking abstinence (CO \< 5) will be measured at the 3-month (secondary endpoint) and 6-month follow-up (primary endpoint) via the valid and reliable TLFB procedure and biochemically verified through a CO \< 5 ppm.

Interventions

  • OTHER HRP Sampling period
  • OTHER NPL Sampling period

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 472 participants
Start Date 2026-01-12
Est. Completion 2030-07
Phase NA

What NCT07199517 shows while recruiting

NCT07199517 is an interventional study that assigns participants to a tested intervention. The registered 472 participants enrollment target is mid-sized for trials with a published cap, above the 373-participant average among 76 other Tobacco Use trials with a reported enrollment target (27% higher).

The record links to 3 conditions, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which HRP Sampling period is the first listed.

NCT07199517 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07199517 about?

NCT07199517 is a clinical study titled "Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit". This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be ran...

What is the current status of trial NCT07199517?

This trial is currently recruiting. It is a NA study. The enrollment target is 472 participants. The study started on 2026-01-12. Estimated completion is 2030-07.

What conditions does trial NCT07199517 study?

This clinical trial studies the following conditions: Tobacco Use, Cigarette Smoking, Cigarette Smoking Behavior.

What interventions are being tested in trial NCT07199517?

The interventions under investigation include: HRP Sampling period (OTHER), NPL Sampling period (OTHER).

Who is sponsoring clinical trial NCT07199517?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07199517 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07199517's enrollment target sits among peer trials

472 13th of 76 higher than 64 of 76 other Tobacco Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06375083 · 472 participants · Phase 2

    Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression

  • NCT06947187 · 472 participants · NA

    Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere

  • NCT07225881 · 472 participants · NA

    Eatwell Clinical Trial (R01)

  • NCT03010150 · 471 participants

    Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07199517, the US trial registry maintained by the National Library of Medicine. NCT07199517 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.